As a part of this pharma partnering agreement, researchers will identify opportunities to change how patients might be treated to improve quality and outcomes for the millions of people who battle diabetes.
Humana, one of the nation’s largest health care companies, and Novo Nordisk, the world leader in diabetes care, will bring together researchers to study the treatment and progression of diabetes in the senior population.
By leveraging both companies’ experience, this research will assist in the development of programs that will further enhance health and well-being of people with diabetes.
Humana, working through its research affiliate, Competitive Health Analytics, Inc., and Novo Nordisk are excited about the opportunity to partner together in the fight against diabetes.
For further deal information visit Current Agreements (subscription required)
Read: more on partnering deals in pharma, biotech, life science partnering deal news, insights and glossary
Report: Practical Guide to Finding Partners
Report: Partnering Deals and Alliances with Novo Nordisk
Report: Bigpharma Partnering Yearbook 2013
View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity